V
41.69
0.12 (0.29%)
| Previous Close | 41.57 |
| Open | 40.71 |
| Volume | 474,170 |
| Avg. Volume (3M) | 893,453 |
| Market Cap | 3,295,559,936 |
| Price / Earnings (TTM) | 109.71 |
| Price / Earnings (Forward) | 27.78 |
| Price / Sales | 6.73 |
| Price / Book | 2.61 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | 7.13% |
| Operating Margin (TTM) | 7.03% |
| Diluted EPS (TTM) | 0.420 |
| Quarterly Revenue Growth (YOY) | 18.20% |
| Total Debt/Equity (MRQ) | 4.23% |
| Current Ratio (MRQ) | 5.10 |
| Operating Cash Flow (TTM) | 89.42 M |
| Levered Free Cash Flow (TTM) | 76.93 M |
| Return on Assets (TTM) | 1.94% |
| Return on Equity (TTM) | 2.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | Veracyte, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.3
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.54% |
| % Held by Institutions | 107.98% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Guggenheim, 19.93%) | Buy |
| Median | 48.00 (15.14%) | |
| Low | 43.00 (Canaccord Genuity, 3.14%) | Hold |
| Average | 46.60 (11.78%) | |
| Total | 3 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 45.58 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 05 Jan 2026 | 50.00 (19.93%) | Buy | 43.63 |
| 05 Nov 2025 | 45.00 (7.94%) | Buy | 46.04 | |
| Morgan Stanley | 02 Dec 2025 | 48.00 (15.14%) | Sell | 46.16 |
| 11 Nov 2025 | 40.00 (-4.05%) | Sell | 42.66 | |
| Canaccord Genuity | 05 Nov 2025 | 43.00 (3.14%) | Hold | 46.04 |
| Needham | 05 Nov 2025 | 44.00 (5.54%) | Buy | 46.04 |
| UBS | 05 Nov 2025 | 48.00 (15.14%) | Buy | 46.04 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Jan 2026 | Announcement | Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results |
| 29 Dec 2025 | Announcement | Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 06 Nov 2025 | Announcement | Veracyte to Participate in Upcoming Investor Conferences |
| 04 Nov 2025 | Announcement | Veracyte Announces Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Announcement | Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |